NCT01454076 - Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

November 10, 2011

Primary Completion Date

April 1, 2015

Study Completion Date

June 16, 2016

Conditions

Nonhematologic MalignanciesLymphoma

Interventions

DRUG

Ixazomib 2.5 mg

Ixazomib 2.5 mg Capsule B (Cycle 1 only)

DRUG

Ixazomib 4 mg Capsule A

Ixazomib 4 mg Capsule A (Cycle 1 only)

DRUG

Ixazomib 4 mg Capsule B

Ixazomib 4 mg Capsule B (Cycle 2 and beyond )

DRUG

Ketoconazole

Ketoconazole 400 mg tablets (Cycle 1 only)

DRUG

Rifampin

Rifampin 600 mg capsule (Cycle 1 only)

DRUG

Clarithromycin

Clarithromycin 500 mg tablets (Cycle 1 only)

DRUG

Ixazomib 4 mg Capsule B

Ixazomib 4 mg Capsule B (Cycle 1 and beyond)

Trial Locations (1)

Dallas